J. Goldman & Co LP Takes $748,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

J. Goldman & Co LP purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 141,748 shares of the company's stock, valued at approximately $748,000. J. Goldman & Co LP owned approximately 0.69% of Protara Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in Protara Therapeutics during the fourth quarter worth $11,938,000. Driehaus Capital Management LLC acquired a new stake in Protara Therapeutics during the fourth quarter worth $2,731,000. Blackstone Inc. acquired a new stake in Protara Therapeutics during the fourth quarter worth $8,870,000. Bank of America Corp DE boosted its stake in Protara Therapeutics by 53,013.9% during the fourth quarter. Bank of America Corp DE now owns 194,397 shares of the company's stock worth $1,026,000 after buying an additional 194,031 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Protara Therapeutics during the fourth quarter worth $802,000. Institutional investors and hedge funds own 38.13% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on TARA shares. Scotiabank started coverage on shares of Protara Therapeutics in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a research note on Monday, April 28th. Lifesci Capital started coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Protara Therapeutics presently has an average rating of "Buy" and a consensus price target of $20.40.

Insider Buying and Selling

In related news, insider Jacqueline Zummo sold 21,224 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now owns 98,861 shares in the company, valued at $447,840.33. This represents a 17.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is owned by corporate insiders.

Protara Therapeutics Trading Up 2.6%

NASDAQ TARA traded up $0.08 on Friday, hitting $3.19. 257,245 shares of the company were exchanged, compared to its average volume of 773,221. The firm has a 50 day moving average of $3.93 and a two-hundred day moving average of $4.13. The company has a market cap of $123.08 million, a P/E ratio of -1.13 and a beta of 1.73. Protara Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.18. Research analysts anticipate that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.